Survival analysis and associated factors in metastatic early-onset colorectal cancer vs. metastatic average-onset colorectal cancer.

• DOI: 10.1200/jco.2024.42.16_suppl.e15549
• Publication Date: 2024-06-04T20:29:33Z
• Authors: Antoine Jeri-Yabar; Liliana Vittini; Sebastian Prado-N...; Sirish Dharmapuri
• Keywords: 03 medical and health sciences; 0302 clinical medicine

e15549 Background: Early-onset colorectal cancer (EO-CRC) is defined as diagnosed before age 50 and its incidence has been increasing during the last decade. Average-onset (AO-CRC) presented a steady decline in related mortality over past 20 years. There controversy surrounding disparities outcomes overall survival (OS) EO-CRC vs. AO-CRC. Our study compared OS cause-specific (CSS) between metastatic (mEO-CRC) AO-CRC (mAO-CRC) identified associated factors. Methods: Data on patient characteristics, tumor were obtained from SEER database 2010 to 2020. We 23,278 individuals aged > 18 with confirmed diagnosis of all histologic subtypes CRC (M1 TNM stage) using ICD-O-3 site code C180, C182-9, C209 histology codes: 8000, 8010, 8012, 8013, 8020-2, 8031-33, 8041, 8045, 8070-2, 8083, 8123-4, 8140, 8144-45, 8201, 8210-11, 8213, 8220-1, 8240, 8243-46, 8249, 8253, 8255, 8260-3, 8261-3, 8265, 8310, 8323, 8480-1, 8490, 8507, 8510, 8550, 8560, 8570, 8574, 8936, 8980. distributions CCS conducted Kaplan-Meier method log-rank test was used assess differences mEO-CRC mAO-CRC. Cox regression model associations variables. Results: constituted 17.79% cases, while 82.21% Most patients 45-49 years old (47.66%), males (52.16%), white (72.57%), adenocarcinoma (87.30%). Left colon tumors most prevalent both groups (40.26%), but higher among than mAO-CRC (49.63% vs 38.23%, p < 0.001). more likely receive chemotherapy (87.23% 66.66%, 0.001) radiotherapy (14.92% 9.51%, 0.001), surgery similar (87.71% 88.52%, = 0.140). Patients had (HR: 1.53, CI 95% 1.47-1.59, well CSS 1.33, CI: 1.27-1.39, when also significantly better median (30 months Factors worse include (p mucinous male sex 0.003) no surgical intervention Conclusions: cancer-directed therapy which could be explained by cohort having performance status, less comorbidities, tolerance cancer-related therapy. are mAO-CRC, adenocarcinoma, lack intervention. Furthermore, it crucial continue studying potential candidates who would benefit early screening.